Aldesleukin Recruiting Phase 1 Trials for Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Fallopian Tube Carcinoma / Primary Peritoneal Cancer / Recurrent Fallopian Tube Carcinoma / Ovarian Carcinoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03017131Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer